Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Packerfan666on Jan 31, 2020 10:26am
64 Views
Post# 30625266

RE:RE:RE:RE:RE:RE:Robert Farrell

RE:RE:RE:RE:RE:RE:Robert FarrellSloomoo. I know your relatively new to board. Ie the last 6 months. And yes I understand that most likely a term sheet is signed. But that's not a guaranteed deal. You weren't here when the last deal they were supposed to have fell through. So excuse my caution. I want Kaly to
suceed, I want to become wealthy, I want all of you to become wealthy. We need to be able to ask the tough questions.  Mine to mr Farrell were these 

1) why didn't we pay talent the 2 million dollar Milestone payment when we had the 10 million PP. he couldn't answer intelligently 
2) I wanted to know if FDA would think the Study size was too small . He admitted that it's possible and admitted that it was a concern of some of interested parties
3) I asked if we had multiple people wanting to offer. He said not at the moment. As parties were having trouble with the balance sheet because all of the warrants etc show up as debt on the liability side. Which they were trying to rectify


of course I am slightly worried. But more importantly I am just looking for answers. But no one can answer them and calls people bashers when they inquire

people on this board Like Maui , Belgium and a bunch can't handle anything that even remotely doesn't blow sunshine up Kalys a$$... it's ridiculous 
Bullboard Posts